DiaMedica Therapeutics In... (DMAC)
undefined
undefined%
At close: undefined
5.38
-0.92%
After-hours Dec 13, 2024, 04:00 PM EST

Company Description

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases.

The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke.

It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases.

The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016.

DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. logo
Country United States
IPO Date Aug 3, 2012
Industry Biotechnology
Sector Healthcare
Employees 18
CEO Dietrich John Pauls MBA

Contact Details

Address:
Two Carlson Parkway
Minneapolis, Minnesota
United States
Website https://www.diamedica.com

Stock Details

Ticker Symbol DMAC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001401040
CUSIP Number 25253X207
ISIN Number CA25253X2077
Employer ID 00-0000000
SIC Code 2834

Key Executives

Name Position
Dietrich John Pauls MBA President, Chief Executive Officer & Director
Dr. Ambarish Shah Ph.D. Chief Technology Officer
Scott Kellen CPA Chief Financial Officer & Corporate Secretary
David J. Wambeke Chief Business Officer
Dominic R. Cundari Chief Commercial Officer
Dr. Lorianne K. Masuoka M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Nov 13, 2024 10-Q Quarterly Report
Nov 13, 2024 8-K Current Report
Aug 07, 2024 8-K Current Report
Aug 07, 2024 10-Q Quarterly Report
Jul 18, 2024 424B3 Filing
Jul 10, 2024 S-3 Filing
Jul 08, 2024 SC 13G Statement of acquisition of beneficial ownership b...
Jul 02, 2024 D Filing
Jul 01, 2024 4 Filing
Jul 01, 2024 4 Filing